Argos Therapeutics (ARGS) Misses Q2 EPS by 5c
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Argos Therapeutics (NASDAQ: ARGS) reported Q2 EPS of ($0.48), $0.05 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $488.64 thousand versus the consensus estimate of $200 thousand.
For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Downgrades Himax Technologies (HIMX) to Neutral
- Citigroup (C) Tops Q4 EPS by 2c
- Commerce Bancshares (CBSH) Tops Q4 EPS by 1c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!